A phase II, single-center, open-label, non-randomized clinical trial evaluated the safety and efficacy of the ATR inhibitor, ceralasertib, in combination with the PD-L1 monoclonal antibody, durvalumab, in patients with advanced gastric cancer. The gene discussed is CD274; the disease is gastric cancer.